Jade Biosciences, Inc. (JBIO) Stock

NASDAQ: JBIOHealthcare company in the biotechnology industry, based in Waltham, MA.

Jade Biosciences stock price chart

JBIO interactive chart →

JBIO stock quote & key statistics

Jade Biosciences earnings per share

Income →
Earnings per share

Jade Biosciences revenue & net income

Income →
RevenueNet income

Jade Biosciences annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$127.4M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Jade Biosciences stock FAQ

What is the Jade Biosciences stock ticker symbol?

Jade Biosciences, Inc. trades on the NASDAQ under the ticker symbol JBIO.

What sector and industry is Jade Biosciences in?

Jade Biosciences, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Jade Biosciences have?

Jade Biosciences, Inc. has about 55 full-time employees.

What were Jade Biosciences's revenue and earnings last fiscal year?

Jade Biosciences reported revenue of $0 and net income of -$127.4M in fiscal 2025.

Is Jade Biosciences in the Russell 2000?

Yes. Jade Biosciences, Inc. (JBIO) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Jade Biosciences go public?

Jade Biosciences stock began trading on June 30, 2021.

Russell 2000 Biotechnology stocks

All Russell 2000 →